What is Zacks Research’s Estimate for BDX FY2025 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Investment analysts at Zacks Research reduced their FY2025 earnings estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Monday, December 16th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $14.39 per share for the year, down from their previous estimate of $14.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.25 EPS, Q2 2026 earnings at $3.83 EPS, Q3 2026 earnings at $4.01 EPS, Q4 2026 earnings at $4.49 EPS and FY2026 earnings at $15.51 EPS.

BDX has been the topic of several other research reports. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Trading Down 0.7 %

Shares of Becton, Dickinson and Company stock opened at $224.09 on Thursday. The stock has a 50 day moving average of $230.29 and a 200 day moving average of $233.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The firm has a market capitalization of $64.79 billion, a price-to-earnings ratio of 37.73, a PEG ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $3.42 EPS.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Arete Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $767,000. Charles Schwab Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in Becton, Dickinson and Company by 2.3% in the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock valued at $135,267,000 after acquiring an additional 12,845 shares in the last quarter. Benson Investment Management Company Inc. lifted its stake in Becton, Dickinson and Company by 13.2% in the third quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after acquiring an additional 2,602 shares during the last quarter. Finally, Swedbank AB grew its holdings in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after acquiring an additional 2,729 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.